Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30795951

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2019 Mar
First author
Gnant M

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Mar;20(3):312-313. doi: 10.1016/S1470-2045(18)30913-6.
    note
    Source null
    related pmid
    30795949
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 May;16(5):272. doi: 10.1038/s41571-019-0197-1.
    note
    Source null
    related pmid
    30837714
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2019 May;20(5):236. doi: 10.1016/S1470-2045(19)30228-1.
    note
    Source null
    related pmid
    31044698
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2019 May;20(5):e233. doi: 10.1016/S1470-2045(19)30181-0.
    note
    Source null
    related pmid
    31044710
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2019 May;20(5):e234-e235. doi: 10.1016/S1470-2045(19)30146-9.
    note
    Source null
    related pmid
    31044711
    relationship
    Comment in

Authors and identifiers

  1. name
    Gnant M
    type
    Author
  2. name
    Pfeiler G
    type
    Author
  3. name
    Steger GG
    type
    Author
  4. name
    Egle D
    type
    Author
  5. name
    Greil R
    type
    Author
  6. name
    Fitzal F
    type
    Author
  7. name
    Wette V
    type
    Author
  8. name
    Balic M
    type
    Author
  9. name
    Haslbauer F
    type
    Author
  10. name
    Melbinger-Zeinitzer E
    type
    Author
  11. name
    Bjelic-Radisic V
    type
    Author
  12. name
    Jakesz R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gnant M
    type
    Author
  2. name
    Pfeiler G
    type
    Author
  3. name
    Steger GG
    type
    Author
  4. name
    Egle D
    type
    Author
  5. name
    Greil R
    type
    Author
  6. name
    Fitzal F
    type
    Author
  7. name
    Wette V
    type
    Author
  8. name
    Balic M
    type
    Author
  9. name
    Haslbauer F
    type
    Author
  10. name
    Melbinger-Zeinitzer E
    type
    Author
  11. name
    Bjelic-Radisic V
    type
    Author
  12. name
    Jakesz R
    type
    Author
bibliography ids
  1. nci-bib-f7df19b0a7c7d5cd2d629b7d
book metadata
content sha256
99eff2b36513f350f211877957188121b78d08cae5f1fefe7e9f2fdc55e32c4a
document type
citation
dois
  1. 10.1016/S1470-2045(18)30862-3
electronic publication date
display
2019 Feb 19
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:30795951
immutable id
pubmed:30795951@99eff2b36513f350f211877957188121b78d08cae5f1fefe7e9f2fdc55e32c4a
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
3
name
The Lancet. Oncology
nlm unique id
100957246
pages
339-351
volume
20
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Mar;20(3):312-313. doi: 10.1016/S1470-2045(18)30913-6.
    note
    Source null
    related pmid
    30795949
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 May;16(5):272. doi: 10.1038/s41571-019-0197-1.
    note
    Source null
    related pmid
    30837714
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2019 May;20(5):236. doi: 10.1016/S1470-2045(19)30228-1.
    note
    Source null
    related pmid
    31044698
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2019 May;20(5):e233. doi: 10.1016/S1470-2045(19)30181-0.
    note
    Source null
    related pmid
    31044710
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2019 May;20(5):e234-e235. doi: 10.1016/S1470-2045(19)30146-9.
    note
    Source null
    related pmid
    31044711
    relationship
    Comment in
outcomes validated
false
pmid
30795951
provenance
batch id
e808962322f3afebc564
provider
NCBI PubMed ESummary
record sha256
2aef107f6b06385fa40be7dd025413cbe2e64fd9d40e2d646ca220d7583d0660
response sha256
3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
retrieved at
2026-09-09T23:47:41.002093+00:00
publication date
display
2019 Mar
precision
month
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30795951/
title
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice